呼出气一氧化氮在下气道慢性炎症疾病中的评估价值

doi:10.16138/j.1673-6087.2022.05.015

摘要/Abstract

中图分类号:

R562

闫晓红, 薄建萍. 呼出气一氧化氮在下气道慢性炎症疾病中的评估价值[J]. 内科理论与实践, 2022, 17(05): 418-422.

YAN Xiaohong, BO Jianping. Value of exhaled nitric oxide in evaluating lower airway chronic inflammatory disease[J]. Journal of Internal Medicine Concepts & Practice, 2022, 17(05): 418-422.

参考文献 45

[1]	Mummadi SR, Hahn PY. Update on exhaled nitric oxide in clinical practice[J]. Chest, 2016, 149(5): 1340-1344. doi: 10.1016/j.chest.2015.11.020 pmid: 26836891
[2]	Harnan SE, Tappenden P, Essat M, et al. Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath[J]. Health Technol Assess, 2015, 19(82): 1-330. doi: 10.3310/hta19820 pmid: 26484874
[3]	Anavi S, Tirosh O. iNOS as a metabolic enzyme under stress conditions[J]. Free Radic Biol Med, 2020, 146: 16-35. doi: 10.1016/j.freeradbiomed.2019.10.411 URL
[4]	Stewart L, Katial RK. Exhaled nitric oxide[J]. Immunol Allergy Clin North Am, 2012, 32(3): 347-362. doi: 10.1016/j.iac.2012.06.005 URL
[5]	Pappalardo MG, Parisi GF, Tardino L, et al. Measurement of nitric oxide and assessment of airway diseases in children: an update[J]. Minerva Pediatr, 2019, 71(6): 524-532. doi: 10.23736/S0026-4946.19.05513-0 pmid: 31352766
[6]	Cyr AR, Huckaby LV, Shiva SS, et al. Nitric oxide and endothelial dysfunction[J]. Crit Care Clin, 2020, 36(2): 307-321. doi: S0749-0704(19)30104-6 pmid: 32172815
[7]	Högman M, Thornadtsson A, Bröms K, et al. Different relationships between FENO and COPD characteristics in smokers and ex-smokers[J]. COPD, 2019, 16(3-4): 227-233. doi: 10.1080/15412555.2019.1638355 pmid: 31357875
[8]	Horváth I, Barnes PJ, Loukides S, et al. A European Respiratory Society technical standard: exhaled biomarkers in lung disease[J]. Eur Respir J, 2017, 49(4): 1600965. doi: 10.1183/13993003.00965-2016 URL
[9]	Hoyte FCL, Gross LM, Katial RK. Exhaled nitric oxide: an update[J]. Immunol Allergy Clin North Am, 2018, 38(4): 573-585. doi: 10.1016/j.iac.2018.06.001 URL
[10]	Arnold RJ, Massanari M, Lee TA, et al. A review of the utility and cost effectiveness of monitoring fractional exhaled nitric oxide (FeNO) in asthma management[J]. Manag Care, 2018, 27(7): 34-41. pmid: 29989900
[11]	GBD 015 Chronic Respiratory Disease Collaborators. 2Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet Respir Med, 2017, 5(9): 691-706. doi: 10.1016/S2213-2600(17)30293-X pmid: 28822787
[12]	Rupani H, Chauhan AJ. Measurement of FeNO in asthma: what the hospital doctor needs to know[J]. Br J Hosp Med (Lond), 2019, 80(2): 99-104. doi: 10.12968/hmed.2019.80.2.99 URL
[13]	Muraro A, Lemanske RF Jr, Hellings PW, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology[J]. J Allergy Clin Immunol, 2016, 137(5): 1347-1358. doi: 10.1016/j.jaci.2016.03.010 URL
[14]	Pavlidis S, Takahashi K, Ng Kee Kwong F, et al. “T2-high” in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin[J]. Eur Respir J, 2019, 53(1): 1800938. doi: 10.1183/13993003.00938-2018 URL
[15]	Spahn JD, Malka J, Szefler SJ. Current application of exhaled nitric oxide in clinical practice[J]. J Allergy Clin Immunol, 2016, 138(5): 1296-1298. doi: S0091-6749(16)30974-5 pmid: 27664377
[16]	Chen LC, Zeng GS, Wu LL, et al. Diagnostic value of FeNO and MMEF for predicting cough variant asthma in chronic cough patients with or without allergic rhinitis[J]. J Asthma, 2021, 58(3): 326-333. doi: 10.1080/02770903.2019.1694035 URL
[17]	中国医药教育协会慢性气道疾病专业委员会, 中国哮喘联盟. 呼出气一氧化氮检测及其在气道疾病诊治中应用的中国专家共识[J]. 中华医学杂志, 2021, 101(38): 3092-3114.
[18]	Halpin DMG, Celli BR, Criner GJ, et al. The GOLD summit on chronic obstructive pulmonary disease in low- and middle-income countries[J]. Int J Tuberc Lung Dis, 2019, 23(11): 1131-1141. doi: 10.5588/ijtld.19.0397 pmid: 31718748
[19]	Mostafavi-Pour-Manshadi SM, Naderi N, Barrecheguren M, et al. Investigating fractional exhaled nitric oxide (FeNO) in chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO): a scoping review protocol[J]. BMJ Open, 2017, 7(12): e018954. doi: 10.1136/bmjopen-2017-018954 URL
[20]	Halpin DMG, Criner GJ, Papi A, et al. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease[J]. Am J Respir Crit Care Med, 2021, 203(1): 24-36. doi: 10.1164/rccm.202009-3533SO URL
[21]	Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease[J]. J Allergy Clin Immunol, 2016, 138(1): 16-27. doi: 10.1016/j.jaci.2016.05.011 pmid: 27373322
[22]	Mostafavi-Pour-Manshadi SM, Naderi N, Barrecheguren M, et al. Investigating fractional exhaled nitric oxide in chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap(ACO)[J]. COPD, 2018, 15(4): 377-391. doi: 10.1080/15412555.2018.1485637 pmid: 30067401
[23]	Yamaji Y, Oishi K, Hamada K, et al. Detection of type2 biomarkers for response in COPD[J]. J Breath Res, 2020, 14(2): 026007. doi: 10.1088/1752-7163/ab71a4 URL
[24]	Tang B, Huang D, Wang J, et al. Relationship of blood eosinophils with fractional exhaled nitric oxide and pulmonary function parameters in chronic obstructive pulmonary disease (COPD) exacerbation[J]. Med Sci Monit, 2020, 26: e921182.
[25]	Antus B, Paska C, Barta I. Predictive value of exhaled nitric oxide and blood eosinophil count in the assessment of airway eosinophilia in COPD[J]. Int J Chron Obstruct Pulmon Dis, 2020, 15: 2025-2035. doi: 10.2147/COPD.S257965 URL
[26]	Gong S, Pu Y, Xie L, et al. Fraction of exhaled nitric oxide is elevated in patients with stable chronic obstructive pulmonary disease[J]. Am J Med Sci, 2020, 360(2): 166-175. doi: 10.1016/j.amjms.2020.04.038 URL
[27]	Matsunaga K, Kuwahira I, Hanaoka M, et al. An official JRS statement: the principles of fractional exhaled nitric oxide (FeNO) measurement and interpretation of the results in clinical practice[J]. Respir Investig, 2021, 59(1): 34-52. doi: 10.1016/j.resinv.2020.05.006 pmid: 32773326
[28]	Rhee CK, Chau NQ, Yunus F, et al. Management of COPD in Asia: a position statement of the Asian Pacific Society of Respirology[J]. Respirology, 2019, 24(10): 1018-1025. doi: 10.1111/resp.13633 pmid: 31276272
[29]	Imam JS, Duarte AG. Non-CF bronchiectasis: orphan disease no longer[J]. Respir Med, 2020, 166: 105940. doi: 10.1016/j.rmed.2020.105940 URL
[30]	Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity[J]. Lancet, 2018, 392(10150): 880-890. doi: S0140-6736(18)31767-7 pmid: 30215383
[31]	Chai YH, Xu JF. How does Pseudomonas aeruginosa affect the progression of bronchiectasis?[J]. Clin Microbiol Infect, 2020, 26(3): 313-318.
[32]	Luo RG, Miao XY, Luo LL, et al. Presence of pldA and exoU in mucoid Pseudomonas aeruginosa is associated with high risk of exacerbations in non-cystic fibrosis bronchiectasis patients[J]. Clin Microbiol Infect, 2019, 25(5): 601-606. doi: 10.1016/j.cmi.2018.07.008 URL
[33]	Tsikrika S, Dimakou K, Papaioannou AI, et al. The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis[J]. Cytokine, 2017, 99: 281-286. doi: S1043-4666(17)30238-7 pmid: 28863927
[34]	Lucas JS, Davis SD, Omran H, et al. Primary ciliary dyskinesia in the genomics age[J]. Lancet Respir Med, 2020, 8(2): 202-216. doi: 10.1016/S2213-2600(19)30374-1 pmid: 31624012
[35]	Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children[J]. Eur Respir J, 2020, 55(1): 1901136. doi: 10.1183/13993003.01136-2019 URL
[36]	Diver S, Russell RJ, Brightling CE. Cough and eosinophilia[J]. J Allergy Clin Immunol Pract, 2019, 7(6): 1740-1747. doi: S2213-2198(19)30457-X pmid: 31279462
[37]	Côté A, Russell RJ, Boulet LP, et al. Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report[J]. Chest, 2020, 158(1): 68-96. doi: S0012-3692(20)30045-3 pmid: 31972181
[38]	Tang W, Zhou J, Miao L, et al. Clinical features in patients of cough variant asthma with normal and high level of exhaled fractional nitric oxide[J]. Clin Respir J, 2018, 12(2): 595-600. doi: 10.1111/crj.12568 pmid: 27731932
[39]	Lamon T, Didier A, Brouquières D, et al. Exhaled nitric oxide in chronic cough: a good tool in a multi-step approach[J]. Respir Med Res, 2019, 76: 4-9. doi: S2590-0412(19)30008-X pmid: 31254946
[40]	Maniscalco M, Fuschillo S, Gaudiosi C, et al. Exhaled and nasal nitric oxide measurement in the evaluation of chronic cough[J]. Nitric Oxide, 2019, 83: 19-23. doi: S1089-8603(18)30311-2 pmid: 30557619
[41]	Swaminathan AC, Carney JM, Tailor TD, et al. Overview and challenges of bronchiolar disorders[J]. Ann Am Thorac Soc, 2020, 17(3): 253-263. doi: 10.1513/AnnalsATS.201907-569CME pmid: 31860801
[42]	He F, Gong HY, Jiang GL, et al. Diffuse panbronchiolitis: a case report from a Chinese consanguineous marriage family and literature review[J]. Chron Respir Dis, 2020, 17: 1479973120961847.
[43]	Faure E, Kwong K, Nguyen D. Pseudomonas aeruginosa in chronic lung infections: how to adapt within the host?[J]. Front Immunol, 2018, 9: 2416. doi: 10.3389/fimmu.2018.02416 URL
[44]	Xu B, Mao Y, Wan X, et al. Prognostic value of concomitant bronchiectasis in newly diagnosed diffuse panbronchiolitis patients on a maintenance therapy with macrolides[J]. Can Respir J, 2019, 2019: 4913814.
[45]	Takeyama K, Shimizu Y, Ishii M, et al. Coexistence of diffuse panbronchiolitis and asthma: reciprocity of neutrophilic and eosinophilic inflammation[J]. Respirol Case Rep, 2017, 5(3): e00232. doi: 10.1002/rcr2.232 URL

呼出气一氧化氮在下气道慢性炎症疾病中的评估价值

Value of exhaled nitric oxide in evaluating lower airway chronic inflammatory disease

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 45

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨玲, 查晴, 张倩茹, 叶佳雯, 杨克, 刘艳. 钙化性主动脉瓣膜病的生物标志物预测模型的构建[J]. 内科理论与实践, 2022, 17(04): 324-329.
[2]	周思锋, 徐海舒, 范欣生. 基于不同生物样本代谢组学的OSAHS生物标志物研究进展[J]. 诊断学理论与实践, 2022, 21(04): 535-540.
[3]	蔡晓波, 王建香, 陆伦根. 胆汁淤积的生物标志物研究进展[J]. 内科理论与实践, 2022, 17(01): 11-14.
[4]	王泽田, 吴春荣, 齐越, 徐丹, 孙科远, 唐建国. 外泌体蛋白质组学分析白念珠菌感染小鼠的标志物[J]. 外科理论与实践, 2021, 26(03): 262-268.
[5]	赵春秀, 王晓龙. 呼出气分析在肺炎病原体诊断中的研究进展[J]. 内科理论与实践, 2021, 16(02): 138-140.
[6]	李圳, 徐志红, 胡家安. 急性肺血栓栓塞症诊断相关生物标志物研究进展[J]. 内科理论与实践, 2021, 16(01): 60-63.
[7]	张雪莹, 秦环龙. 肠道菌群作为结肠直肠癌生物标志物及其干预的临床意义[J]. 外科理论与实践, 2020, 25(02): 155-158.
[8]	陈海燕, 杨小宝, 许大康. 新生物标志物在胃肠道肿瘤中疗效预测和预后价值的研究进展[J]. 诊断学理论与实践, 2019, 18(06): 704-710.
[9]	罗清琼, 陈福祥. 肿瘤免疫治疗策略的转变及相关标志物研究现状[J]. 诊断学理论与实践, 2019, 18(04): 387-393.
[10]	吴颖燕, 姚谦, 程琦,. 早期帕金森病生物标志物的研究进展[J]. 内科理论与实践, 2019, 14(04): 259-264.
[11]	曹丽辰, 田宝星, 瞿飞麟, 张庆华, 郭善禹. 乳腺癌转移病人血清外泌体蛋白质分析[J]. 外科理论与实践, 2019, 24(02): 141-148.
[12]	杜坤, 杨喜, 卞炳贤, 任懿倩, 张广慧. 血清presepsin(sCD14-ST)、降钙素原、C反应蛋白和白介细胞素-6诊断血流细菌感染的诊断性能比较[J]. 诊断学理论与实践, 2018, 17(05): 581-585.
[13]	陈晓农, 汪知玉,. 新型骨相关生物标志物在慢性肾脏病血管钙化中的应用价值[J]. 内科理论与实践, 2018, 13(04): 202-206.
[14]	崔诗爽, 陈生弟, 王刚. 帕金森病体液生物标志物研究进展[J]. 诊断学理论与实践, 2018, 17(04): 471-476.
[15]	由佳音, 陈桢玥,. 心力衰竭生物标志物新进展[J]. 内科理论与实践, 2017, 12(06): 422-426.